CAT and OGS in US$176 M Merger
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 33 (Table of Contents)
Published: 3 Feb-2003
DOI: 10.3833/pdr.v2003.i33.943 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Cambridge Antibody Technology (CAT) and Oxford Glycosciences (OGS) entered into a merger agreement designed to create one of the strongest biotechnology companies in Europe...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018